{"Accident": 2.4722783194442024, "Acute kidney injury": 2.4663961500023026, "Adenocarcinoma": 13.404970129232462, "Adrenal insufficiency": 12.208079834863709, "Adrenocorticotropic hormone deficiency": 26.996241241787075, "Adverse event": 3.386883259911374, "Anaemia": 2.2393685052237435, "Atelectasis": 2.2283607107322103, "Atrioventricular block complete": 3.719051999336321, "Autoimmune colitis": 49.979273710275706, "Autoimmune haemolytic anaemia": 11.952697636026326, "Autoimmune hepatitis": 14.372157104986156, "Autoimmune hypothyroidism": 86.86038597547537, "Autoimmune nephritis": 77.25340791481104, "Autoimmune thyroiditis": 11.735728824410394, "Blood thyroid stimulating hormone increased": 5.544790770129857, "Bronchiectasis": 2.298775061160313, "Cachexia": 4.193280860097438, "Cardiac tamponade": 4.039601876622272, "Central nervous system lesion": 5.045058277188986, "Cholangitis": 3.661292524588848, "Cholangitis sclerosing": 16.055249456052806, "Cholecystitis": 2.175927106380916, "Colitis": 13.474927436668647, "Colitis microscopic": 4.974370275844997, "Conjunctivitis": 2.27775391484738, "Cortisol decreased": 11.872056966218144, "Cytokine release syndrome": 3.1609458975146016, "Cytopenia": 2.7189619777506304, "Dermatitis": 3.5903019365419584, "Dermatitis bullous": 3.483598648842467, "Diabetic ketoacidosis": 5.312034656407763, "Drug effective for unapproved indication": 15.53391670002147, "Drug-induced liver injury": 3.3280057510779453, "Eastern Cooperative Oncology Group performance status worsened": 23.19249218843331, "Emphysema": 2.354118053353282, "Encephalitis": 5.745263753749124, "Encephalitis autoimmune": 24.49146152563375, "Enterocolitis": 3.135333840619102, "Eosinophilic fasciitis": 70.55753608928401, "Eyelid ptosis": 4.886720248597092, "Febrile neutropenia": 3.438665614813203, "Fulminant type 1 diabetes mellitus": 35.50204880131232, "Gastritis": 2.2074963936590506, "Gastrointestinal toxicity": 4.178889296420048, "General physical health deterioration": 2.876584457726812, "Groin pain": 2.294421122722232, "Guillain-Barre syndrome": 3.498801080312312, "Haematotoxicity": 4.317281802221969, "Haemophagocytic lymphohistiocytosis": 5.397031303734889, "Hepatitis": 7.479053367345931, "Hepatitis toxic": 3.760940600477056, "Hepatotoxicity": 6.908549875594698, "Hydronephrosis": 3.826931012806324, "Hyperthyroidism": 7.739652271170485, "Hypertransaminasaemia": 9.422480830953967, "Hypophysitis": 41.52946791044046, "Hypopituitarism": 11.89062836850796, "Hypothyroidism": 16.803681739659414, "Immune thrombocytopenia": 3.804638369177528, "Immune-mediated adrenal insufficiency": 12.180790553386824, "Immune-mediated adverse reaction": 218.3609962337172, "Immune-mediated arthritis": 225.40112169505903, "Immune-mediated dermatitis": 110.28158389102845, "Immune-mediated encephalitis": 88.12473905802388, "Immune-mediated enterocolitis": 87.01238917414331, "Immune-mediated gastritis": 138.7524362437781, "Immune-mediated hepatic disorder": 17.701328577193927, "Immune-mediated hepatitis": 159.58314858683067, "Immune-mediated hyperthyroidism": 79.04636038738231, "Immune-mediated hypophysitis": 68.77202184071163, "Immune-mediated hypothyroidism": 108.50116229004126, "Immune-mediated lung disease": 252.2892549395408, "Immune-mediated myasthenia gravis": 142.77021930411232, "Immune-mediated myocarditis": 222.94764746283224, "Immune-mediated myositis": 163.01045574735727, "Immune-mediated nephritis": 97.78667643242784, "Immune-mediated neuropathy": 76.48327868180448, "Immune-mediated pancreatitis": 106.9043138221212, "Immune-mediated renal disorder": 41.02675963556282, "Immune-mediated thyroiditis": 272.9166595203233, "Immune-mediated uveitis": 87.2453277067317, "Inappropriate schedule of product administration": 4.670403836466642, "Interstitial lung disease": 3.3046686483804706, "Intestinal perforation": 2.3067639838674494, "Lichen planus": 8.727841268758885, "Lichenoid keratosis": 15.454466373047763, "Lung adenocarcinoma": 8.449394920990414, "Lung consolidation": 7.838807834756025, "Lymphocytic hypophysitis": 41.168308194680186, "Malignant neoplasm progression": 22.542974688033237, "Metastases to adrenals": 16.599441420957305, "Metastases to central nervous system": 2.047833824749328, "Metastases to lung": 2.144551292427279, "Mucosal inflammation": 5.087410200169902, "Multi-organ disorder": 20.003984388988357, "Myasthenia gravis": 26.21331138377178, "Myasthenia gravis crisis": 30.415613830161785, "Myasthenic syndrome": 33.766362411198386, "Myocarditis": 5.850787012379521, "Myopathy": 2.699256162964448, "Myositis": 17.1484350431254, "Nephritis": 31.09310465190787, "Nephropathy toxic": 4.461130603064338, "Neutropenia": 2.758685607294053, "Neutropenic sepsis": 4.578492528267693, "Non-small cell lung cancer": 4.548645602882062, "Non-small cell lung cancer metastatic": 35.323071885692684, "Ocular myasthenia": 45.9761589140098, "Off label use": 2.225803050590541, "Ophthalmoplegia": 8.031566335549025, "Organising pneumonia": 12.522191324237964, "Palmar-plantar erythrodysaesthesia syndrome": 2.638441682756686, "Pancytopenia": 3.199901310890544, "Pemphigoid": 17.850807819216865, "Performance status decreased": 2.68896051844864, "Pericardial effusion": 2.186564009862297, "Pleural effusion": 2.3751192125863034, "Pneumocystis jirovecii pneumonia": 2.3489207356030346, "Pneumonitis": 30.103912837156034, "Pneumothorax": 2.0161010317528567, "Polyarthritis": 17.232033861551173, "Polymyalgia rheumatica": 13.49310077332168, "Posterior reversible encephalopathy syndrome": 3.855617041895293, "Prescribed underdose": 3.812461611938893, "Primary hypothyroidism": 87.02433046204894, "Product use in unapproved indication": 5.701012376006535, "Product use issue": 5.151879892776317, "Proteinuria": 4.052412746862008, "Psoriasis": 2.412047978438032, "Pulmonary fibrosis": 2.343701687445632, "Pulmonary toxicity": 8.068596274511483, "Radiotherapy": 31.935016428110057, "Rash maculo-papular": 2.118146022169461, "Renal cyst": 3.613222121489709, "Renal tubular necrosis": 8.047633531453819, "Respiratory failure": 2.170282112165836, "Sarcoidosis": 8.470409785933315, "Secondary adrenocortical insufficiency": 18.56480101248293, "Sjogren's syndrome": 8.423050300994403, "Skin infection": 3.2698175091552164, "Skin toxicity": 24.155496534535125, "Stevens-Johnson syndrome": 2.870500766998736, "Therapy non-responder": 6.448236394734161, "Therapy partial responder": 97.88908181114392, "Thyroiditis": 18.042315370165326, "Toxic epidermal necrolysis": 5.781438134847835, "Troponin increased": 2.3391313445131177, "Tubulointerstitial nephritis": 15.03106955936286, "Tumour hyperprogression": 286.3438936491698, "Tumour pseudoprogression": 184.117515946807, "Type 1 diabetes mellitus": 29.25924766727108, "Uveitis": 3.4373673442543686, "Vasculitis": 2.93095414895782, "Vitiligo": 44.42319349079082}